Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 16/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943514 | 0.99 | HPGD (0.58) | HPGDALDH1A1NPC1GLARAB9A | |
| SCHEMBL2944419 | 0.91 | HPGD (0.58) | HPGDALDH1A1NPC1GLARAB9A | |
| SCHEMBL6752853 | 0.90 | HPGD (0.59) | HPGDALDH1A1NPC1GLARAB9A | |
| SCHEMBL7241895 | 0.85 | HPGD (0.56) | HPGDALDH1A1NPC1GLARAB9A | |
| SCHEMBL2652689 | 0.85 | FGFR1 (0.69) | HPGDALDH1A1NPC1GLARAB9A | |
| SCHEMBL6752588 | 0.84 | HPGD (0.54) | HPGDALDH1A1NPC1GLARAB9A | |
| SCHEMBL2648342 | 0.83 | FGFR1 (0.59) | HPGDALDH1A1NPC1GLARAB9A | |
| SCHEMBL2641999 | 0.82 | FGFR1 (0.64) | HPGDALDH1A1NPC1GLARAB9A | |
| SCHEMBL2651150 | 0.82 | HPGD (0.49) | HPGDALDH1A1NPC1GLARAB9A | |
| SCHEMBL2647587 | 0.80 | FGFR1 (0.68) | HPGDALDH1A1NPC1GLARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934281-B1 | 1-PHENYL-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS BAGA- A? RECEPTOR MODULATORS | NEUROSEARCH AS (DK) | 2010-01-06 | — | — | EP | claimed |
| US-20030166638-A1 | Benzimidazole's used as aminobutyric acid receptor modulators, for prophylaxis of nervous system disorders such as anxiety, sleep disorders, epilepsia or convulsions | NEUROSEARCH A/S | 2003-09-04 | — | — | US | claimed |
| US-6218547-B1 | 1-phenyl-benzimidazole compounds and their use as GABA-a receptor modulators | NEUROSEARCH A/S (DK) | 2001-04-17 | — | — | US | claimed |
| EP-0934281-B1 | 1-PHENYL-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS BAGA- A? RECEPTOR MODULATORS | NEUROSEARCH AS (DK) | 2010-01-06 | — | — | EP | disclosed |
| US-6710044-B2 | Technical field | NEUROSEARCH A/S (DK) | 2004-03-23 | — | — | US | disclosed |
| US-20030166638-A1 | Benzimidazole's used as aminobutyric acid receptor modulators, for prophylaxis of nervous system disorders such as anxiety, sleep disorders, epilepsia or convulsions | NEUROSEARCH A/S | 2003-09-04 | — | — | US | disclosed |
| US-6503925-B1 | Treating anxiety, anesthesia, and epilepsy | NEUROSEARCH A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| US-6218547-B1 | 1-phenyl-benzimidazole compounds and their use as GABA-a receptor modulators | NEUROSEARCH A/S (DK) | 2001-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166638-A1 | Benzimidazole's used as aminobutyric acid receptor modulators, for prophylaxis of nervous system disorders such as anxiety, sleep disorders, epilepsia or convulsions | GABRA1, GABRA2, GABRA4 | HPGD 1806/4885ALDH1A1 192/4885NPC1 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.